Allogene Frustrated By FDA’s Delayed CAR-T Trial Review
ALLO-510A Awaits Green Light To Start Phase II Study
Allogene wants to maintain its lead in the allo CAR-T field, but is facing a slow decision-making on its lead candidate. • Source: Shutterstock 
